These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 9859573)

  • 21. The original sin committed in years two thousand.
    Cortese B
    J Interv Cardiol; 2011 Oct; 24(5):424-5. PubMed ID: 21929731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?
    Brener SJ
    J Am Coll Cardiol; 2009 May; 53(18):1674-6. PubMed ID: 19406343
    [No Abstract]   [Full Text] [Related]  

  • 23. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
    Stone GW; Moliterno DJ; Bertrand M; Neumann FJ; Herrmann HC; Powers ER; Grines CL; Moses JW; Cohen DJ; Cohen EA; Cohen M; Wolski K; DiBattiste PM; Topol EJ
    Circulation; 2002 May; 105(20):2347-54. PubMed ID: 12021219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism.
    Gowda RM; Khan IA; Vasavada BC; Sacchi TJ
    Am J Ther; 2004; 11(4):302-7. PubMed ID: 15266223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria.
    Kini AS; Reich D; Mitre CA; Sharma SK
    Am J Cardiol; 2001 Dec; 88(11):1287-90. PubMed ID: 11728356
    [No Abstract]   [Full Text] [Related]  

  • 26. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study.
    Moliterno DJ; Topol EJ
    Am Heart J; 2000 Nov; 140(5):722-6. PubMed ID: 11054616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors.
    Aster RH
    Chest; 2005 Feb; 127(2 Suppl):53S-59S. PubMed ID: 15706031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment.
    Brown DL
    Heart; 2003 May; 89(5):535-7. PubMed ID: 12695459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes.
    Tcheng JE
    Am Heart J; 1999 Oct; 138(4 Pt 2):261-2. PubMed ID: 10502231
    [No Abstract]   [Full Text] [Related]  

  • 31. Glycoprotein IIb/IIIa inhibitors.
    Stevens M
    Intensive Crit Care Nurs; 2002 Feb; 18(1):64-6. PubMed ID: 12008879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycoprotein IIb-IIIa antagonists in percutaneous coronary interventions and acute coronary syndromes.
    Ramanathan A; Kleiman NS
    Indian Heart J; 1998 Oct; 50 Suppl 1():45-56. PubMed ID: 9824907
    [No Abstract]   [Full Text] [Related]  

  • 33. An audit of the use and complications of glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention against national UK standards.
    Sheikh A; Baig K
    Cardiovasc Revasc Med; 2006; 7(4):237-9. PubMed ID: 17174871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New thrombocyte aggregation inhibitor in therapy of unstable angina].
    Hamm C
    Z Kardiol; 2000 Nov; 89(11):1053-6. PubMed ID: 11149273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
    Dorsch MP; Montague D; Rodgers JE; Patterson C
    Pharmacotherapy; 2006 Mar; 26(3):423-7. PubMed ID: 16503724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
    Dunn A
    Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice.
    Young JJ; Kereiakes DJ
    J Interv Cardiol; 2002 Apr; 15(2):115-20. PubMed ID: 12063806
    [No Abstract]   [Full Text] [Related]  

  • 38. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
    Tcheng JE
    Am J Cardiol; 1999 May; 83(9A):7E-11E. PubMed ID: 10357575
    [No Abstract]   [Full Text] [Related]  

  • 39. Beyond aspirin: how glycoprotein inhibitors ease acute coronary syndromes.
    MacCallum EM; Hanlon SJ; Byrne KH
    Nursing; 1999 Dec; 29(12):34-9; quiz 40. PubMed ID: 10797693
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors.
    Brouse SD; Wiesehan VG
    Ann Pharmacother; 2004 Nov; 38(11):1783-8. PubMed ID: 15383640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.